The pandemic and lockdown caused by COVID-19 have increased symptoms of anxiety and depression in the population. However, according to a major sur...
Hospital Clínic de Barcelona-IDIBAPS and Cellnex have today signed an agreement to launch a multicentre research project that will allow better und...
Researchers of IDIBAPS have participated in an interdisciplinary research study of the UB in which there have been identified two potential candida...
Hospital Clínic – IDIBAPS (Barcelona) has founded Gyala Therapeutics, a new spin-off company focused on developing new CAR-T therapies for treating...
Researchers from the Respiratory biophysics and bioengineering IDIBAPS research group, the Biophysics and Bioengineering Unit of the UB and the CIB...
Uveitis is a disease that causes inflammation of the tissues inside the eye. More specifically, non-infectious uveitis (NIU) causes 20% of cases of...
Today the results of the phase 2 CORALLEEN clinical trial, promoted by the international academic group SOLTI, have been presented. The study, publ...
Researchers at IDIBAPS, CIBERehd and ICFO implement gold nanoparticles and plasmonics to treat liver fibrosis in mice.
A study coordinated by researchers of the Clínic-IDIBAPS and published in The Lancet Gastroenterology & Hepatology establishes the safe dose of sim...